Introduction: Atopic dermatitis (AD) has been related to a deficiency of delta-6-desaturase, an enzyme responsible for the conversion of linoleic acid to gamma-linolenic acid (GLA).
INTRODUCTION
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by eczematous lesions, skin dryness, and severe itch [1] . AD affects 15-30% of children and 2-10% of adults [1] . The etiopathology of AD is multifactorial and includes a genetic predisposition towards disrupted skin barrier function and allergic inflammation as well as environmental factors [2] . Defects of the skin barrier (e.g., due to mutations of the filaggrin gene) lead to an increased irritability followed by inflammatory processes [3] .
At least in a subset of patients with AD, a malfunction of delta-6-desaturase seems to play a pathogenetic role [4] . This enzyme is responsible for the conversion of linoleic acid (LA) to gamma-linolenic acid (GLA), which is further metabolized to dihomo-gammalinolenic acid (DGLA). DGLA is the precursor of prostaglandin E1 (PGE1) or 15-hydroxyeicosatrienoic acid (15-HETrE) [5] .
As a result of a reduced enzyme activity of delta-6-desaturase, high levels of LA and low levels of GLA have been observed in AD patients [6] . Accordingly, less DGLA and its metabolites PGE1 and 15-HETrE known to have antiinflammatory capacity are produced [5] .
Supplementation with GLA, a component of evening primrose oil (EPO), is assumed to lead to increased concentrations of GLA and DGLA in blood, thereby supporting anti-inflammatory responses [7] . Indeed, GLA supplementation studies in humans and rodents have shown that the synthesis of anti-inflammatory PGE1, but not pro-inflammatory PGE2, was selectively elevated [8] .
The EPO preparation used in this study contained high amounts of GLA (80 mg/ 1,000 mg EPO) with sufficient bioavailability after oral intake [9] . The clinical efficacy of EPO supplementation in AD has been shown in numerous studies [10] [11] [12] . Nevertheless, the use of EPO has been judged controversially [10, 13, 14] ; moreover, a measurable biomarker for the possible efficacy of EPO has not yet been described.
This 
METHODS

Study Design
The study was designed as a prospective, taking part in another study or had taken an investigational product during the last 4 weeks before the start of treatment were not allowed to take part in the study.
The study participants were allowed to continue to use any medication which they had been taking prior to the study at the same dose, unless the medication could be discontinued or was listed as prohibited medication. Prohibited medication prior to study start and during the study were as follows. Thirty days prior to study start, physical or psychological therapy, antiinflammatory medication to treat AD, and immuno-modulating medication were not allowed. Fourteen days prior to study start, non-steroidal anti-rheumatic drugs, systemic use of glucocorticosteroids, tranquillizers or antiemetic agents from the phenothiazine group were forbidden and 7 days prior to study start alpha-or beta-blockers, clonidine, alpha-sympathomimetic medication, azelastine, levocabastine, or antidepressants
were not allowed to be taken by the patient. The objective SCORing Atopic Dermatitis (SCORAD) index [16] and plasma GLA and DGLA levels were assessed before treatment (baseline) and 4 and 12 weeks after treatment initiation. As safety parameters, the occurrence of adverse events (AEs), hematological and clinical-chemical laboratory tests, and vital signs were assessed. A total of 36 patients were screened and 13 screening failures occurred; forbidden medication (pimecrolimus, antidepressants; n = 2), holidays (n = 2), refusal of blood sampling (n = 1), no interest to participate (n = 1), not possible to participate (n = 1), and no reason specified (n = 6).
Study Medication
The study medication (EPOGAM Ò 1000, Zeller Medical AG, Romanshorn, Switzerland) contained 932-1,073 mg EPO (Oenothera seminis oleum), corresponding to 80 mg GLA per capsule. The dosages were two capsules twice daily for patients aged 2-12 years and three capsules twice daily for patients over 12 years. Treatment duration was 12 weeks.
Treatment compliance was defined as intake of at least 75% of the trial medication. Rescue medication including prednicarbate cream 0.25% (Prednitop Ò , Abbott AG, Baar, Switzerland) and hydroxyzine syrup 2 mg/ml (Atarax Ò ; UCB Pharma, Bulle, Switzerland) was disposed to coup eczema exacerbations and pruritus, respectively.
Blood Sample Analysis
The DGLA and GLA measurements were performed at AZ Biopharm GmbH (Berlin, Germany). To stabilize fatty acids, butylated hydroxytoluene was added and blood was stored at -20°C. As published elsewhere [17] , absolute levels of GLA and DGLA in human plasma were determined applying a gas chromatographic method with mass selective detection. Additionally, safety laboratory parameters [routine parameters of blood count and blood chemistry as well as Immunoglobulin E (IgE) levels] were measured locally at each investigator's site laboratory.
Statistics
To compare SCORAD and fatty acid levels at baseline, week 4 and week 12, data were tested by non-parametric Wilcoxon Signed Rank Test for paired samples for the intention-to-treat 
RESULTS
Patients
Objective SCORAD Significantly Decreased
The clinical efficacy of EPO was assessed in the ITT population by recording the objective SCORAD at baseline, 4 weeks and 12 weeks after initiation of EPO therapy. At baseline, 42.9% of the patients had mild symptoms (objective SCORAD \25) and 57.1% had moderate symptoms (objective SCORAD 25-50), according to Oranje et al. [16] . After the 12-week treatment period, 93.2% of the patients had mild symptoms, whereas only 6.8% had moderate symptoms. Accordingly, the mean objective SCORAD showed a timedependent reduction with a statistically significant decrease after 4 and 12 weeks, respectively, compared to baseline ( Fig. 1 ; Supplemental Table 1 in the Electronic Supplementary Material). With specific focus on SCORAD parameters, a significant decrease in both the extent and total intensity of AD after EPO treatment was noticed ( Table 1 ). In addition, the intensity of individual AD symptoms except for weeping/crusting was significantly reduced. Supplementation of EPO had no effect on total IgE levels (data not shown).
Total SCORAD Significantly Decreased
In line with the results obtained for the objective SCORAD, the clinical efficacy of EPO could also be confirmed for the total SCORAD. The mean total SCORAD showed a timedependent reduction with a statistically significant decrease after 4 (P = 0.019) and 12 weeks (P = 0.001), respectively. Results of all individual SCORAD parameters are illustrated in Table 1 .
Increase in Plasma Fatty Acid Levels
Inversely Correlated with SCORAD
In the ITT population, the plasma levels of both GLA and DGLA showed a significant increase over the study period ( Fig. 2 ; Supplemental Table 1 in the Electronic Supplementary Material). This increase was most evident from baseline to week 4, with no relevant further increase to week 12. For the PP population, it could be shown that the reduction of the objective SCORAD was inversely correlated with the increase in plasma GLA (Fig. 3 ). In the ITT population, the correlation of the objective SCORAD and plasma GLA was not significant (data not shown) For DGLA, no significant correlation could be demonstrated (P = 0.36; data not shown).
Usage of Rescue Medication did not Affect
Study Outcome
While EPO represents a long-term basic therapy for AD, the usage of concomitant treatment options reflects the usual practice. Patients were allowed to use the provided rescue medication (prednicarbate cream and hydroxyzine syrup), for example, in cases of severe itching. The influence of the co-medication was evaluated in the ITT population (n = 21). During the study, rescue medication was used by the majority of patients (71.4%). A total of nine patients used hydroxyzine (syrup, 10-50 mg orally). Twelve patients used prednicarbate (cream, 0.25% topically) as rescue (Table 2 ). However, the patient groups relying on rescue medication did not show any significant difference regarding the improvement of the objective SCORAD compared to the group without usage of concomitant anti-pruritic medication (P = 0.20 and P = 0.89, respectively). 
Safety
DISCUSSION
This study showed that supplementation with EPO had significant effects on clinical improvement of clinical signs in patients with AD in association with an increase in plasma GLA and DGLA levels. This is in line with previous studies, revealing the clinical effect of EPO after 4-8 weeks of treatment [10] . The present study showed further improvement of AD symptoms upon 12 weeks, supporting the idea that EPO should be applied as long-term basic therapy.
Low peripheral blood levels of GLA and DGLA have been reported in patients with AD [18] . Supplementation with EPO containing relevant amounts of GLA resulted in a significant increase in GLA and DGLA plasma levels in our AD patient group. Since GLA and DGLA can be metabolized to 15-HETrE and PGE1 in the skin, a deficit in GLA might result Table 1 Elements of the objective and the total SCORAD (mean ± SD) in the intention-to-treat population (n = 21) at baseline and at last visit (Wilcoxon Signed Rank Test) The objective SCORAD formula is A/5 + 7B/2. The total SCORAD formula is: A/5 + 7B/2 + C, where, A extent (rule of nine in %) of AD, B sum of intensity of 6 symptoms erythema, edema, weeping/crusting, excoriation, lichenification, dryness of skin of AD (B1-B6), and C subjective symptoms (0-20) AD atopic dermatitis, SCORAD SCORing Atopic Dermatitis, VAS visual analog score in a reduced production of these antiinflammatory metabolites [5] . Thus, low GLA levels might contribute to inflammation of allergic diseases. Accordingly, GLA levels inversely correlated with total serum IgE levels [18] . It has been shown that in children with AD receiving GLA supplementation have a lower SCORAD compared to the placebo group [19] .
SCORAD items
The increase in plasma GLA concentration was significantly inversely correlated with AD severity [19] . Moreover, a placebo-controlled study investigating the effect of borage oil containing at least 23% GLA showed a clinical improvement of AD, in particular, in those patients in whom an increase in erythrocyte DGLA levels was found [20] . In agreement with these reports, a significant reduction of clinical signs in a group of pediatric and adult AD patients treated with EPO as assessed by objective SCORAD was observed. Moreover, the increase in GLA plasma levels upon supplementation with EPO was associated with a reduction of the objective SCORAD. This effect was observed as early as 4 weeks after initiating EPO therapy.
Remarkably, the significance of these preliminary results could be obtained despite the small sample size. The difference in plasma GLA levels might be an appropriate marker to identify responders. Thus, AD patients benefitting from EPO could be selected 4 weeks after initiating supplementation and be given advice to continue EPO supplementation. Patients without an increase in plasma GLA after 4 weeks although receiving EPO supplementation might most likely be 
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As necessary 2-87 n.a. Not applicable the study. The study protocol was approved by the cantonal ethics committees and the regulatory agency.
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